Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016847 · ClinicalTrials.gov registry record · Phase 4
Moderate to Persistent Asthma in the Obese Subject
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT01016847 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 38 participants.
The verdict
NCT01016847, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
Obesity is associated with increased airway inflammation and asthma severity that results in suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS). The investigators suggested that the addition of Singular (montelukast)\[LTRA\] to moderate doses of inhaled corticosteroids will improve asthma control. This cross over study will be treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12 weeks.
Interventions
- DRUG Montelukast
- OTHER Sugar pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016847
The ClinicalTrials.gov registry entry for NCT01016847 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Montelukast is the first listed.
NCT01016847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01016847 about?
NCT01016847 is a clinical study titled "Moderate to Persistent Asthma in the Obese Subject". Obesity is associated with increased airway inflammation and asthma severity that results in suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS). The investigators suggested that the addition of Singular (montelukast)\[LTRA\] to moderate doses of inhaled cortico...
What is the current status of trial NCT01016847?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2010-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01016847?
The interventions under investigation include: Montelukast (DRUG), Sugar pill (OTHER).
Who is sponsoring clinical trial NCT01016847?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.